Guillermo Alberto De Angulo, MD
Pediatric Emergency Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Angulo’s office at (650) 723-0000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A168544 · Current
Licensed to practise in California · since 2020 · expires 2028-04-30 · Medical University of South Carolina College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$106,293 in 2024
Medicaid paid $106,293 for 1,079 billed services this clinician did in 2024, up to 92 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| EMERGENCY DEPT VISIT MOD MDM | 571 | $58,276 |
| EMERGENCY DEPARTMENT VISIT HIGH MDM | 203 | $28,301 |
| EMERGENCY DEPT VISIT LOW MDM | 288 | $19,059 |
| Service | 17 | $657 |
| 2024 | 1,079 | 4 | 92 | $106,293 |
| 2023 | 1,202 | 5 | 83 | $93,602 |
| 2022 | 1,521 | 3 | 89 | $90,195 |
| 2021 | 1,183 | 6 | 73 | $60,444 |
| 2020 | 369 | 3 | 59 | $24,010 |
| 2019 | 96 | 1 | 28 | $7,026 |
See the largest Medicaid services in earlier years
2023
| EMERGENCY DEPT VISIT LOW MDM | 708 | $46,732 |
| EMERGENCY DEPT VISIT MOD MDM | 385 | $35,762 |
| EMERGENCY DEPARTMENT VISIT HIGH MDM | 80 | $10,155 |
| Service | 17 | $642 |
| EMERGENCY DEPARTMENT VISIT STRAIGHTFORWARD MDM | 12 | $311 |
2022
| EMERGENCY DEPT VISIT MOD MDM | 781 | $70,666 |
| EMERGENCY DEPARTMENT VISIT STRAIGHTFORWARD MDM | 719 | $19,172 |
| EMERGENCY DEPARTMENT VISIT MAY NOT REQ PHYS/QHP | 21 | $356 |
2021
| EMERGENCY DEPT VISIT MOD MDM | 531 | $40,606 |
| EMERGENCY DEPARTMENT VISIT STRAIGHTFORWARD MDM | 487 | $13,148 |
| EMERGENCY DEPARTMENT VISIT HIGH MDM | 24 | $2,818 |
| EMERGENCY DEPT VISIT LOW MDM | 34 | $1,674 |
| EMERGENCY DEPARTMENT VISIT MAY NOT REQ PHYS/QHP | 83 | $1,315 |
| Service | 24 | $884 |
2020
| EMERGENCY DEPT VISIT LOW MDM | 268 | $14,555 |
| EMERGENCY DEPT VISIT MOD MDM | 76 | $6,136 |
| EMERGENCY DEPARTMENT VISIT HIGH MDM | 25 | $3,319 |
2019
| EMERGENCY DEPT VISIT LOW MDM | 96 | $7,026 |
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · A Phase II, Open-Label, Single Arm Study To Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (Pkc412) Combined With Standard Chemotherapy and As A Single Agent Post-Consolidation Therapy in Children With Untreated Flt3-Mutated Aml · 2023 | Their institution | $8,564 |
| Novartis Pharmaceuticals Corporation · A Phase II, Open-Label, Single Arm Study To Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (Pkc412) Combined With Standard Chemotherapy and As A Single Agent Post-Consolidation Therapy in Children With Untreated Flt3-Mutate · 2022 | Their institution | $408 |
| Novartis Pharmaceuticals Corporation · A Phase II, Open-Label, Single Arm Study To Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (Pkc412) Combined With Standard Chemotherapy and As A Single Agent Post-Consolidation Therapy in Children With Untreated Flt3-Mutate · 2020 | Their institution | $408 |
| Novartis Pharmaceuticals Corporation · A Phase II, Open-Label, Single Arm Study To Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (Pkc412) Combined With Standard Chemotherapy and As A Single Agent Post-Consolidation Therapy in Children With Untreated Flt3-Mutated Aml · 2021 | Their institution | $408 |
| Novartis Pharmaceuticals Corporation · A Phase II, Open-Label, Single Arm Study To Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (Pkc412) Combined With Standard Chemotherapy and As A Single Agent Post-Consolidation Therapy in Children With Untreated Flt3-Mutated Aml · 2024 | Their institution | $408 |
Professional record
- NPI
- 1588921241
- Licence
- CA A168544, NY 277884California A168544: Current · expires 2028-04-30
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207PP0204X (207PP0204X); Pediatrics (208000000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2012-04-19
- NPI last updated
- 2024-03-21
- NPI record certified
- 2024-03-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 525 E 68th St, New York, NY, 10065 · 1189 Welch Rd, Palo Alto, CA, 94304